Free Trial

Ainos Q4 2022 Earnings Report

Ainos logo
$0.45 +0.01 (+2.50%)
(As of 12/20/2024 05:23 PM ET)

Ainos Earnings Headlines

Ainos announces IRB approval for Sjogren’s Syndrome clinical study
Your chance to get on the next “60-Second Trade”
Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!
Ainos files complaints over concerns about unsual trading activity
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD), a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

View Ainos Profile

More Earnings Resources from MarketBeat

Upcoming Earnings